Research Topics
| MARTIN H MARKOWITZSummaryAffiliation: Aaron Diamond AIDS Research Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 studyMartin Markowitz
Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, NY 10016, USA
J Acquir Immune Defic Syndr 45:401-10. 2007....
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infectionMartin Markowitz
Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University, New York, New York, USA
J Infect Dis 201:1298-302. 2010..Adjunctive therapy with cyclosporine in this setting does not provide apparent virologic or immunologic benefit...- Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infectionSaurabh Mehandru
Aaron Diamond AIDS Research Centre and the Rockefeller University, New York, NY 10016, USA
Expert Opin Investig Drugs 12:1821-8. 2003..TPV dosed twice-daily, in the range of 500 - 1250 mg and combined with 100 - 200 mg of RTV has been shown to substantially and durably reduce viral load in HIV-1-infected drug-naive and experienced patients... - Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccinationMartin Markowitz
Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
J Infect Dis 186:634-43. 2002.... - Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case reportMartin Markowitz
Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
Lancet 365:1031-8. 2005..Here, we describe a patient in whom these two factors arose concomitantly and assess the effects... - A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivoMartin Markowitz
Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
J Virol 77:5037-8. 2003..7 day, and the generation time of HIV-1 in vivo, approximately 2 days, confirming the dynamic nature of HIV-1 replication... - Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patientsMartin Markowitz
The Aaron Diamond AIDS Research Center, New York, NY 10016, USA
J Acquir Immune Defic Syndr 39:257-64. 2005..The ESS40013 study tested 4-drug induction followed by 3-drug maintenance as initial antiretroviral therapy (ART) to reduce HIV RNA rapidly and then to simplify to an effective yet more convenient and tolerable regimen... - Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replicationBharat Ramratnam
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
J Acquir Immune Defic Syndr 35:33-7. 2004..Additional studies are needed to understand the host- and pathogen-related determinants of incomplete pharmacologic control of HIV-1 replication... - Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experienceAnita Shet
Aaron Diamond AIDS Research Center (an affiliate of the Rockefeller University, New York, NY 10016, USA
J Acquir Immune Defic Syndr 41:439-46. 2006.... - Determining the relative efficacy of highly active antiretroviral therapyMichael Louie
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, NY 10016, USA
J Infect Dis 187:896-900. 2003..Nevertheless, we believe that optimal treatment regimens for HIV-1 have yet to be identified and that continued research to achieve this goal is warranted... 
In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progressionHiroshi Mohri
Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
J Acquir Immune Defic Syndr 48:511-21. 2008..In 2005, we reported a case of transmitted MDR HIV-1 infection associated with dual tropism and rapid clinical progression. Here we report the in vitro characterization of the virus isolates...- Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infectionSaurabh Mehandru
Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Ave, 7th Fl, New York, NY 10016, USA
J Virol 81:599-612. 2007..Subsequently, ongoing infection of susceptible CD4+ T cells, along with activation-induced cellular death and host cytotoxic cellular response, are responsible for the persistence of the lesion... 
Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infectionSaurabh Mehandru
Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, United States of America
PLoS Med 3:e484. 2006..Although clinically silent over the short term, the long-term consequences of the persistence of this lesion may emerge as the HIV-1-infected population survives longer owing to the benefits of HAART...- Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individualsViviana Simon
Aaron Diamond AIDS Research Center, The Rockefeller University, New York 1016, USA
AIDS 16:1511-9. 2002..The latter findings suggest transmission of viruses from subjects who have either changed or discontinued therapy... - Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trialsRoy T Steigbigel
State University of New York at Stony Brook, The Rockefeller University, New York, New York, USA
Clin Infect Dis 50:605-12. 2010.... - Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapyXia Jin
Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, 7th Floor, New York, NY 10016, USA
J Virol 76:2206-16. 2002..In summary, vaccination with vCP1452 and recombinant gp160 appears safe and immunogenic in newly HIV-1-infected patients on HAART... - Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical courseNicole Prada
Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, NY 10016, USA
J Acquir Immune Defic Syndr 49:117-22. 2008..Attenuated infection with failure of tenofovir as prophylaxis has been reported in animal models. Here, we report a case of HIV-1 infection despite intermittent use of fixed-dose combination tenofovir and emtricitabine (FTC)... - Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infectionSandhya Vasan
Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
Int Immunol 19:943-51. 2007..Finally, preservation of NKT cell function may be important in HIV-infected individuals, as NKT cells display an anti-HIV-1 activity in vitro, mediated by IFN-gamma secretion... - Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individualsMichael Louie
Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
AIDS 17:1151-6. 2003..These data support further study of TDF-based regimens in simplified combinations of antiviral agents as initial treatment for chronic HIV-1 infection... - Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infectionSaurabh Mehandru
Aaron Diamond AIDS Research Center, 455 First Avenue, 7th Floor, New York, NY 10016, USA
J Virol 81:11016-31. 2007..Though safe, the use of MAbs generally delayed, but did not prevent, virologic rebound. Consideration should be given to further pilot studies with alternative combinations of MAbs and perhaps additional novel treatment modalities... - Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccineSandhya Vasan
Aaron Diamond AIDS Research Center, New York, New York, United States of America
PLoS ONE 5:e8617. 2010..Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective was to evaluate the safety and immunogenicity of ADVAX in human volunteers... - Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyMartin Markowitz
Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY, USA
J Acquir Immune Defic Syndr 46:125-33. 2007..This study explored the antiretroviral activity and safety of raltegravir in treatment-naive patients with plasma HIV-1 RNA levels > or = 5000 copies/mL and CD4 T-cell counts > or = 100 cells/mm... - Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tractSaurabh Mehandru
Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Fl, New York, NY 10016, USA
J Exp Med 200:761-70. 2004..Given the importance of the mucosal compartment in HIV-1 pathogenesis, further study to elucidate the significance of the changes observed here is critical... - Transmitted multidrug resistant HIV-1: new and investigational therapeutic approachesAnita Shet
Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, NY 10016, USA
Curr Opin Investig Drugs 7:709-20. 2006.... - Predictors of response to highly active antiretroviral therapyAndrea Low
Rockefeller University, New York, USA
AIDS Read 16:425-8, 430-1, 434, 436. 2006..The factors that are predictors of response to antiretroviral therapy, including adherence, stage of disease at baseline, treatment history, and demographic factors, are discussed... - The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infectionSaurabh Mehandru
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
J Allergy Clin Immunol 116:419-22. 2005..Ongoing work in this field is likely to have a significant effect on HIV research in the near future... - The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapyJerome K Percus
Courant Institute of Mathematical Sciences, New York University, New York, NY 10012, USA
Bull Math Biol 65:263-77. 2003.... - Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infectionViviana Simon
Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
J Virol 77:7736-45. 2003..Further studies are needed to elucidate the precise regions that are essential for these characteristics... - Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspectiveMichael Louie
Aaron Diamond AIDS Research Center, 455 First Ave, 7th Floor, New York, NY 10016, USA
Antiviral Res 55:15-25. 2002..In this article, we discuss the issues surrounding the initiation of HAART, and describe the virologic and immunologic milestones that may be achieved with effective antiretroviral therapy... - Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionMartin Markowitz
Aaron Diamond AIDS Research Center, New York, NY, USA
J Acquir Immune Defic Syndr 52:350-6. 2009..The purpose of this study was to evaluate the safety and efficacy of raltegravir vs efavirenz-based antiretroviral therapy after 96 weeks in treatment-naive patients with HIV-1 infection... - Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsMartin Markowitz
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
J Acquir Immune Defic Syndr 43:509-15. 2006..Based on these results, part 2 of the study, a dose-ranging 48-week trial of MK-0518 versus efavirenz in a combination regimen, has been initiated... - Raltegravir: an integrase inhibitor for HIV-1Teresa H Evering
The Aaron Diamond AIDS Research Center Rockefeller University, 455 First Avenue, New York, NY 10016, USA
Expert Opin Investig Drugs 17:413-22. 2008..Raltegravir has been shown to specifically inhibit the essential, HIV-1-encoded, integrase enzyme. As a result, this agent represents a promising chemotherapeutic agent for the treatment of HIV/AIDS... - Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1Teresa Hope Evering
Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
Drugs Today (Barc) 43:865-77. 2007..S. Food and Drug Administration (FDA) for the treatment of HIV-1 as part of combination antiretroviral therapy in treatment-experienced patients-providing an additional option for the management of the HIV-1 infected individual... - Evidence of dysregulation of dendritic cells in primary HIV infectionRachel Lubong Sabado
New York University, School of Medicine, Cancer Institute, New York, NY, USA
Blood 116:3839-52. 2010..Taken together, our data demonstrate that despite the reduction in circulating DC numbers, those that remain in the blood display hyperfunctionality and implicates a possible role for DCs in promoting chronic immune activation... - Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapyMichael A Poles
New York University School of Medicine Department of Medicine, New York, New York, USA
J Virol 77:10456-67. 2003.... - Colonization and subsequent skin and soft tissue infection due to methicillin-resistant Staphylococcus aureus in a cohort of otherwise healthy adults infected with HIV type 1Anita Shet
Aaron Diamond AIDS Research Center, New York, New York, USA
J Infect Dis 200:88-93. 2009..Previous antibiotic use was the only statistically significant risk factor for MRSA carriage. These data highlight the fact that MRSA colonization and infection are important clinical issues among asymptomatic HIV-1-infected individuals... - Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10Saurabh Mehandru
Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
J Virol 78:14039-42. 2004..We propose that the induction of 4E10-like antibodies should be a priority in designing immunogens to prevent HIV-1 infection... - Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitorsAndrea Low
Aaron Diamond AIDS Research Center, an affiliate of the Rockefeller University, 455 First Avenue, New York, NY 10016, USA
Antimicrob Agents Chemother 53:4275-82. 2009..Most of the highly prevalent polymorphisms have little effect on InSTI susceptibility in the absence of specific primary mutations. Baseline testing for integrase susceptibility in InSTI-naïve patients is not currently warranted... - DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypesLeonia Bozzacco
Laboratories of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10021, USA
Proc Natl Acad Sci U S A 104:1289-94. 2007..Because of the consistency in eliciting CD8+ T cell responses, these data support the testing of alphaDEC-205 fusion mAb as a protein-based vaccine...
Research Grants
- The Transmission and Fitness of Drug Resistant HIV-1Martin Markowitz; Fiscal Year: 2009..abstract_text> ..
- The Transmission and Fitness of Drug Resistant HIV-1Martin Markowitz; Fiscal Year: 2007....
- Understanding and Altering the Virologic SetpointMartin Markowitz; Fiscal Year: 2006..abstract_text> ..
- TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1Martin Markowitz; Fiscal Year: 2004..Finally, to further understand the viral dynamics of multi-drug resistant viruses, in vivo interventional studies will be performed in individuals to deduce parameters of drug resistant virus replication in vivo. ..
- The Transmission and Fitness of Drug Resistant HIV-1MARTIN H MARKOWITZ; Fiscal Year: 2011..abstract_text> ..